Healthcare / Drug Manufacturers - Specialty & GenericBSE
$13.63
+0.04 (+0.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-67.6M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.2B
P/E
21.0x
↑EV/EBITDA
24.3x
↑ROE
25.5%
↑Gross Margin
36.8%
↓Debt/Equity
0.83
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.2%
FCF CAGR
—
FCF margin
-19.2%
FCF / Net income
-1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.20B · net income $205.2M · FCF $-230.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.20B | $1.20B | $665.8M | $1.13B | $571.4M |
| Net Income | $205.2M | $205.2M | $96.6M | $58.2M | $-1.1M |
| EBITDA | $324.3M | $324.3M | $157.2M | $126.5M | $58.4M |
| EPS | 0.39 | 0.39 | 0.18 | 0.11 | -0.00 |
| Gross Margin | 36.8% | 36.8% | 45.3% | 21.7% | 22.6% |
| Operating Margin | 25.7% | 25.7% | 20.8% | 9.8% | 6.5% |
| Net Margin | 17.1% | 17.1% | 14.5% | 5.2% | -0.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.83 | 0.83 | 3.86 | 9.54 | 40.14 |
| Current Ratio | 2.87 | 2.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-230.8M | $-230.8M | $-67.6M | $-32.2M | $-22.3M |
| Returns | |||||
| ROE | 25.5% | 25.5% | 45.9% | 78.9% | -6.9% |
| Valuation | |||||
| P/E | 20.97 | 20.97 | — | — | — |
| EV/EBITDA | 24.35 | 24.35 | — | — | — |
| P/B | 9.01 | 9.01 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 80.7% | 80.7% | -41.0% | 97.5% | — |
| EPS Growth | 112.5% | 112.5% | 65.9% | 5504.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
46.3%
EPS terminal req.
$1.21
Spread vs growth
66.1%
5Y implied EPS CAGR
30.5%
EPS terminal req.
$1.46
Spread vs growth
81.9%
10Y implied EPS CAGR
19.8%
EPS terminal req.
$2.36
Spread vs growth
92.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+48.7%
Start / end P/E
50.4x → 35.3x
EPS bridge
0.18 → 0.39
Residual
-33.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.